<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0120-8705</journal-id>
<journal-title><![CDATA[CES Medicina]]></journal-title>
<abbrev-journal-title><![CDATA[CES Med.]]></abbrev-journal-title>
<issn>0120-8705</issn>
<publisher>
<publisher-name><![CDATA[Universidad CES]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0120-87052017000100070</article-id>
<article-id pub-id-type="doi">10.21615/cesmedicina.31.1.7</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Bombas de insulina en diabetes tipo 2, del fundamento a la práctica]]></article-title>
<article-title xml:lang="en"><![CDATA[Pumps in Type 2 diabetes, from basics to practice]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Álvarez]]></surname>
<given-names><![CDATA[María Fernanda]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Palacio-Barrientos]]></surname>
<given-names><![CDATA[Andrés]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Botero-Arango]]></surname>
<given-names><![CDATA[José Fernando]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rámirez-Rincón]]></surname>
<given-names><![CDATA[Alex]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universitaria Bolivariana  ]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad Pontificia Bolivariana  ]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2017</year>
</pub-date>
<volume>31</volume>
<numero>1</numero>
<fpage>70</fpage>
<lpage>76</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0120-87052017000100070&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0120-87052017000100070&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0120-87052017000100070&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen Las bombas de insulina han sido usadas por más de 35 años, principalmente en pacientes con diabetes tipo 1 y en menor medida en diabetes tipo 2. En esta última población hay una liberación más funcional de insulina, se puede prevenir el fenómeno de alba y mantener por más tiempo los niveles adecuados de glucemia. Las indicaciones de bomba en diabetes tipo 2 son poco claras, pero los que tal vez más se benefician son aquellos con historia de mal control metabólico, hipoglucemias severas o asintomáticas. El uso de esta tecnología durante la hospitalización ha sido difícil, principalmente por el desconocimiento del personal de salud en su uso; no obstante, se ha demostrado que es factible mantener a los pacientes en esta terapia mientras están hospitalizados, siempre y cuando se tenga un adecuado protocolo, disposición del personal y educación del paciente. El costo ha sido una de las cuestiones más controversiales con el uso de estos sistemas. Los análisis de costo-efectividad han encontrado una disminución del número de hipoglucemiantes orales, las visitas a urgencias y las dosis de insulina, llegando algunos a aseverar que en tres años podrían compensarse los costos.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Insulin pumps have been used for over 35 years, mostly in patients with type 1 diabetes and to a lesser extent in type 2 diabetes. The use of pumps in this population is supported by a more physiological release of insulin, prevention of the dawn phenomenon and enabling patients to achieve better glucose targets. Pump indications in type 2 diabetes are less clear than in patients with type 1, but perhaps those who benefit most, are patients with a history of significant glycemic excursions, severe or asymptomatic hypoglycemia. Pump management as inpatient has been limited by lack of personal knowledge, however it has been reported that it is feasible to keep patients who are using this technology to continue it while they are in the hospital provided that a suitable protocol has been standardized and the patient has enough knowledge. Costs have been one of the most controversial issues with the use of these technology, cost-effectiveness analysis have found that there is a decrease in the number of oral agents, emergency room visits and insulin doses, reaching some studies to conclude that three years could offset the pump cost.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Sistemas de Infusión de Insulina]]></kwd>
<kwd lng="es"><![CDATA[Páncreas artificial]]></kwd>
<kwd lng="es"><![CDATA[Diabetes tipo 2]]></kwd>
<kwd lng="es"><![CDATA[Hemoglobina A Glicosilada]]></kwd>
<kwd lng="es"><![CDATA[Hospitalización]]></kwd>
<kwd lng="en"><![CDATA[Insulin infusion systems]]></kwd>
<kwd lng="en"><![CDATA[Artificial pancreas, Type 2 diabetes, Hemoglobin A1c, Glycosylated]]></kwd>
<kwd lng="en"><![CDATA[Hospital admission]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Closed-loop insulin delivery in type 1 diabetes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thabit]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Hovorka]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Endocrinol Metab Clin North Am]]></source>
<year>2012</year>
<volume>41</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>105-17</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[CSII in Europe: where are we, where are we going? An analysis of articles published in Infusystems International]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Selam]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes Res Clin Pract]]></source>
<year>2006</year>
<volume>74</volume>
<page-range>S123-6</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Automation control of blood sugar. i. a servomechanism for glucose monitoring and control]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kadish]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Med Electron]]></source>
<year>1964</year>
<volume>3</volume>
<page-range>82-6</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[OmniPod insulin management system: patient perceptions, preference, and glycemic control]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zisser]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Jovanovic]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes Care]]></source>
<year>2006</year>
<volume>29</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>2175</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Comparison of pharmacokinetic properties, physicochemical stability, and pump compatibility of 3 rapid-acting insulin analogues-aspart, lispro, and glulisine]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bode]]></surname>
<given-names><![CDATA[BW]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Endocrinol]]></source>
<year>2011</year>
<volume>17</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>271-80</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Prevention of nocturnal hypoglycemia using predictive alarm algorithms and insulin pump suspension]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Buckingham]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Chase]]></surname>
<given-names><![CDATA[HP]]></given-names>
</name>
<name>
<surname><![CDATA[Dassau]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Cobry]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Clinton]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Gage]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes Care]]></source>
<year>2010</year>
<volume>33</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1013-7</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Prevention of hypoglycemia by using low glucose suspend function in sensor-augmented pump therapy]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Danne]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Kordonouri]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Holder]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Haberland]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Golembowski]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Remus]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes Technol Ther]]></source>
<year>2011</year>
<volume>13</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1129-34</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Insulin pump therapy vs. multiple daily injections in obese Type 2 diabetic patients]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wainstein]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Metzger]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Boaz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Minuchin]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Yaffe]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabet Med]]></source>
<year>2005</year>
<volume>22</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1037-46</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Delays in minimally invasive continuous glucose monitoring devices: a review of current technology]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Keenan]]></surname>
<given-names><![CDATA[DB]]></given-names>
</name>
<name>
<surname><![CDATA[Mastrototaro]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Voskanyan]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Steil]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
</person-group>
<source><![CDATA[J Diabetes Sci Technol]]></source>
<year>2009</year>
<volume>3</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1207-14</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Measurement delay associated with the Guardian RT continuous glucose monitoring system]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wei]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Lunn]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Acerini]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
<name>
<surname><![CDATA[Allen]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Larsen]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Wilinska]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabet Med J Br Diabet Assoc]]></source>
<year>2010</year>
<volume>27</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>117-22</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The artificial pancreas: current status and future prospects in the management of diabetes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Peyser]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Dassau]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Breton]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Skyler]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
</person-group>
<source><![CDATA[Ann N Y Acad Sci]]></source>
<year>2014</year>
<volume>1311</volume>
<page-range>102-23</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Insulin pump use in type 2 diabetes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bode]]></surname>
<given-names><![CDATA[BW]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes Technol Ther]]></source>
<year>2010</year>
<volume>12</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>S17-21</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Three-year efficacy of complex insulin regimens in type 2 diabetes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Holman]]></surname>
<given-names><![CDATA[RR]]></given-names>
</name>
<name>
<surname><![CDATA[Farmer]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Davies]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Levy]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Darbyshire]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Keenan]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
</person-group>
<source><![CDATA[N Engl J Med]]></source>
<year>2009</year>
<volume>361</volume>
<numero>18</numero>
<issue>18</issue>
<page-range>1736-47</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Consensus Statement by the American Association of Clinical Endocrinologists/American College of Endocrinology Insulin Pump Management Task Force]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grunberger]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Abelseth]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Bailey]]></surname>
<given-names><![CDATA[TS]]></given-names>
</name>
<name>
<surname><![CDATA[Bode]]></surname>
<given-names><![CDATA[BW]]></given-names>
</name>
<name>
<surname><![CDATA[Handelsman]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Hellman]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Endocr Pract]]></source>
<year>2014</year>
<volume>20</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>463-89</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Treatment with intravenous insulin followed by continuous subcutaneous insulin infusion improves glycaemic control in severely resistant Type 2 diabetic patients]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pouwels]]></surname>
<given-names><![CDATA[M-JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Tack]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Hermus]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Lutterman]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabet Med J Br Diabet Assoc]]></source>
<year>2003</year>
<volume>20</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>76-9</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The use of continuous insulin delivery systems in severely insulin-resistant patients]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wainstein]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Metzger]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Wexler]]></surname>
<given-names><![CDATA[ID]]></given-names>
</name>
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Raz]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes Care]]></source>
<year>2001</year>
<volume>24</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1299</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Continuous Subcutaneous Insulin Infusion and Multiple Daily Injection Therapy Are Equally Effective in Type 2 Diabetes A randomized, parallel-group, 24-week study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Raskin]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Bode]]></surname>
<given-names><![CDATA[BW]]></given-names>
</name>
<name>
<surname><![CDATA[Marks]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Hirsch]]></surname>
<given-names><![CDATA[IB]]></given-names>
</name>
<name>
<surname><![CDATA[Weinstein]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[McGill]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes Care]]></source>
<year>2003</year>
<volume>26</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>2598-603</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A Clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 Diabetes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Herman]]></surname>
<given-names><![CDATA[WH]]></given-names>
</name>
<name>
<surname><![CDATA[Ilag]]></surname>
<given-names><![CDATA[LL]]></given-names>
</name>
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Martin]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
<name>
<surname><![CDATA[Sinding]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Harthi]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes Care]]></source>
<year>2005</year>
<volume>28</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1568-73</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Long-term treatment combining continuous subcutaneous insulin infusion with oral hypoglycaemic agents is effective in type 2 diabetes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Labrousse-Lhermine]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Cazals]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Ruidavets]]></surname>
<given-names><![CDATA[J-B]]></given-names>
</name>
<name>
<surname><![CDATA[GEDEC Study Group]]></surname>
</name>
<name>
<surname><![CDATA[Hanaire]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes Metab]]></source>
<year>2007</year>
<volume>33</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>253-60</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Insulin pump therapy in patients with type 2 diabetes safely improved glycemic control using a simple insulin dosing regimen]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Edelman]]></surname>
<given-names><![CDATA[SV]]></given-names>
</name>
<name>
<surname><![CDATA[Bode]]></surname>
<given-names><![CDATA[BW]]></given-names>
</name>
<name>
<surname><![CDATA[Bailey]]></surname>
<given-names><![CDATA[TS]]></given-names>
</name>
<name>
<surname><![CDATA[Kipnes]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Brunelle]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes Technol Ther]]></source>
<year>2010</year>
<volume>12</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>627-33</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Comparison of continuous subcutaneous insulin infusion and insulin glargine-based multiple daily insulin aspart injections with preferential adjustment of basal insulin in patients with type 2 diabetes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gao]]></surname>
<given-names><![CDATA[G-Q]]></given-names>
</name>
<name>
<surname><![CDATA[Heng]]></surname>
<given-names><![CDATA[X-Y]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[Y-L]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[W-X]]></given-names>
</name>
<name>
<surname><![CDATA[Dong]]></surname>
<given-names><![CDATA[Q-Y]]></given-names>
</name>
<name>
<surname><![CDATA[Liang]]></surname>
<given-names><![CDATA[C-G]]></given-names>
</name>
</person-group>
<source><![CDATA[Exp Ther Med]]></source>
<year>2014</year>
<volume>8</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1191-6</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Transitioning insulin pump therapy from the outpatient to the inpatient setting: a review of 6 years&#8217; experience with 253 cases]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cook]]></surname>
<given-names><![CDATA[CB]]></given-names>
</name>
<name>
<surname><![CDATA[Beer]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Seifert]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Boyle]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Mackey]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Castro]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<source><![CDATA[J Diabetes Sci Technol]]></source>
<year>2012</year>
<volume>6</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>995-1002</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Guidelines for application of continuous subcutaneous insulin infusion (insulin pump) therapy in the perioperative period]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Boyle]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Seifert]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Beer]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Apsey]]></surname>
<given-names><![CDATA[HA]]></given-names>
</name>
<name>
<surname><![CDATA[Nassar]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Littman]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
</person-group>
<source><![CDATA[J Diabetes Sci Technol]]></source>
<year>2012</year>
<volume>6</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>184-90</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Use of continuous subcutaneous insulin infusion (insulin pump) therapy in the hospital setting: proposed guidelines and outcome measures]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cook]]></surname>
<given-names><![CDATA[CB]]></given-names>
</name>
<name>
<surname><![CDATA[Boyle]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Cisar]]></surname>
<given-names><![CDATA[NS]]></given-names>
</name>
<name>
<surname><![CDATA[Miller-Cage]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Bourgeois]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Roust]]></surname>
<given-names><![CDATA[LR]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes Educ]]></source>
<year>2005</year>
<volume>31</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>849-57</page-range></nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Resource utilization with insulin pump therapy for type 2 diabetes mellitus]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lynch]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Riedel]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Samant]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Fan]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Peoples]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Levinson]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Manag Care]]></source>
<year>2010</year>
<volume>16</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>892-6</page-range></nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Insulin pump for type 2 diabetes: use and misuse of continuous subcutaneous insulin infusion in type 2 diabetes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reznik]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes Care]]></source>
<year>2013</year>
<volume>36</volume>
<numero>^s2</numero>
<issue>^s2</issue>
<supplement>2</supplement>
<page-range>S219-25</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
